Literature DB >> 25797235

The risk of stillbirth and infant death by each additional week of expectant management in twin pregnancies.

Jessica M Page1, Rachel A Pilliod2, Jonathan M Snowden3, Aaron B Caughey3.   

Abstract

OBJECTIVE: The objective of the study was to compare the fetal/infant mortality risk associated with each additional week of expectant management with the mortality risk of immediate delivery in women with twin gestations. STUDY
DESIGN: A retrospective cohort study was performed utilizing 2006-2008 National linked birth certificate and death certificate data. The incidence of stillbirth and infant death were determined for each week of pregnancy from 32 0/7 weeks' through 40 6/7 weeks' gestation. Pregnancies complicated by fetal anomalies were excluded. These measures were combined to estimate the theoretic risk of remaining pregnant an additional week by adding the risk of stillbirth during the extra week of pregnancy with the risk of infant death encountered with delivery during the following week. This composite fetal/infant mortality risk was compared with the risk of infant death associated with delivery at the corresponding gestational age.
RESULTS: The risk of stillbirth increased with increasing gestational age, for example, between 37 and 38 weeks' gestation (12.5 per 10,000 vs 22.5 per 10,000; P<.05). As expected, the risk of infant death following delivery gradually decreased as pregnancies approached term gestation. Week-by-week differences were statistically significant (P<.05) between 32 and 36 weeks with decreasing risk of infant death at advancing gestational ages. The composite risk of stillbirth and infant death associated with an additional week of pregnancy had a significant increase from 37 to 38 weeks' gestation (43.9 per 10,000 vs 59.2 per 10,000; P<.05). At 37 weeks' gestation, the relative risk of mortality was statistically significantly lower with immediate delivery as compared with expectant management (relative risk, 0.87; 95% confidence interval, 0.77-0.99).
CONCLUSION: Our results suggest that fetal/infant death risk is minimized at 37 weeks' gestation; however, individual maternal and fetal characteristics must also be taken into account when determining the optimal timing of delivery for twin pregnancies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  expectant management; infant death; stillbirth; twin pregnancy

Mesh:

Year:  2015        PMID: 25797235     DOI: 10.1016/j.ajog.2015.03.033

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  Optimal Timing of Delivery Based on the Risk of Stillbirth and Infant Death Associated with Each Additional Week of Expectant Management in Multiple Pregnancies: a National Cohort Study of Koreans.

Authors:  Hyun Sun Ko; Sae Kyung Choi; Jeong Ha Wie; In Yang Park; Yong Gyu Park; Jong Chul Shin
Journal:  J Korean Med Sci       Date:  2018-03-05       Impact factor: 2.153

2.  Perinatal and postpartum care during the COVID-19 pandemic: A nationwide cohort study.

Authors:  Michael Wagner; Veronica Falcone; Sabrina B Neururer; Hermann Leitner; Irmgard Delmarko; Herbert Kiss; Angelika Berger; Alex Farr
Journal:  Birth       Date:  2021-10-07       Impact factor: 3.081

3.  Prevalence and outcomes of twin pregnancies in Botswana: a national birth outcomes surveillance study.

Authors:  Arielle Isaacson; Modiegi Diseko; Gloria Mayondi; Judith Mabuta; Sonya Davey; Mompati Mmalane; Joseph Makhema; Denise L Jacobson; Rebecca Luckett; Roger L Shapiro; Rebecca Zash
Journal:  BMJ Open       Date:  2021-10-21       Impact factor: 2.692

4.  Australian national birthweight percentiles by sex and gestational age for twins, 2001-2010.

Authors:  Zhuoyang Li; Mark P Umstad; Lisa Hilder; Fenglian Xu; Elizabeth A Sullivan
Journal:  BMC Pediatr       Date:  2015-10-08       Impact factor: 2.125

5.  A Consilience of Inductions Supports the Extended Fetuses-at-Risk Model.

Authors:  K S Joseph
Journal:  Paediatr Perinat Epidemiol       Date:  2016-01       Impact factor: 3.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.